BioPharmaSpec expands European operations with new facility in Vilnius

BioPharmaSpec, a contract research organization (CRO) specializing in biopharmaceutical analysis, has announced plans to open a new facility in Vilnius early next year. The company’s Lithuanian division will provide discovery research and preclinical characterization services for a range of biopharmaceutical products.  
Founded in 2014 by leading experts in biopharmaceutical characterization, BioPharmaSpec has built a strong reputation for providing advanced analytical services to the rapidly evolving biopharmaceutical industry. The company’s expansion to Lithuania significantly strengthens its European operations, alongside its new sites in Germany and Italy.  

"After evaluating several locations across the EU and Switzerland, Lithuania emerged as a clear choice for our expansion. The combination of a well-educated talent pool and a reasonable cost base, along with the country's growing biotech industry, aligns perfectly with our strategic goals", said Prof. Howard Morris, BioPharmaSpec founder.

The new Lithuanian facility will focus on discovery and R&D services, offering preclinical characterization services for various biopharmaceutical products. These include monoclonal antibodies, antibody-drug conjugates, gene therapy products, bioactive peptides, oligonucleotides, carbohydrates, and product and process impurities analysis.  
 In Lithuania, BioPharmaSpec will be recruiting chemists, biochemists, and biologists educated at BS and PhD levels. The new hires will join the company’s team of more than 40 employees across its locations in North America, the UK, India, and Europe.  
BioPharmaSpec also plans to explore collaborations with Lithuanian higher education institutions and other stakeholders. The company has an extensive track record of successful partnerships with academia, industry, and regulatory bodies such as the FDA, some of which have led to joint publications.